Actively Recruiting
Evaluating LuX-Valve Plus System Versus EVOQUE for Severe Tricuspid Regurgitation Safety and Effectiveness Clinical Trial
Led by Jenscare Innovation Inc. · Updated on 2026-08-28
680
Participants Needed
7
Research Sites
469 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the LuX-Valve Plus system to see if it helps treat adults with severe or greater tricuspid regurgitation, a heart valve condition. This trial compares the LuX-Valve Plus system to a conventional device called EVOQUE to evaluate their effectiveness and safety in treating this condition. The goal is to understand how well the LuX-Valve Plus works and its safety profile in patients with significant tricuspid valve leakage. Participants will undergo one procedure using either the LuX-Valve Plus system or the EVOQUE device after passing screening and enrolling in the trial. The study includes a randomized group where participants receive either LuX-Valve Plus or EVOQUE, and a single-arm group for those not suitable for the EVOQUE procedure who will receive LuX-Valve Plus. Both devices are used to replace the tricuspid valve through a minimally invasive, transvenous approach. During the trial, participants will attend follow-up visits and have examinations as outlined in the study protocol. Researchers will monitor for major adverse events within 30 days after the procedure and assess overall clinical success at 12 months. Participants will also report any side effects or issues they experience. The study is led by Jenscare Innovation Inc. and aims to collect important safety and effectiveness data while following patients over time.
CONDITIONS
Brief Title
Pivotal Trial to Evaluate TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (The TRINITY Pivotal Trial)
Research Team
C
Chen Jiao, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here